Iain Ross
Chairman at SILENCE THERAPEUTICS PLC
Net worth: 197 697 $ as of 2023-11-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Derek Lindsay | M | 62 |
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | 8 years |
| John Friend | M | 54 | 3 years | |
| John Hawkins | M | 58 | 10 years | |
| Craig Tooman | M | 58 | 3 years | |
| James Robert Mead | M | 46 | 6 years | |
| Megan Boston | F | 52 |
Benitec Biopharma Ltd.
 Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 8 years |
| Michael Kauffman | M | 60 | 2 years | |
| Peter Presland | M | 75 | 7 years | |
| Graham Dick | M | 73 | 9 years | |
| Frank Beechinor-Collins | M | 60 | 10 years | |
| Ahmad Mortazavi | M | 53 | 4 years | |
| Dominic Nicholas Jackson | M | - |
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | 3 years |
| Martin Walton | M | 61 | 2 years | |
| J. Buchi | M | 69 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 11 years |
| Alistair Gray | M | 75 | 9 years | |
| Lisa Anson | F | - | 6 years | |
| Gem Hopkins | M | - | 4 years | |
| Marie Wikström Lindholm | M | - | 7 years | |
| Rhonda L. Hellums | F | 52 | 3 years | |
| Robert Hawkins | M | 69 | 3 years | |
| Ebru Davidson | F | - | 1 years | |
| Michael Owen | M | 73 | 9 years | |
| Elise Brownell | M | - | 10 years | |
| Barbara Staehelin | F | 61 | 3 years | |
| Steven Romano | M | 64 | 5 years | |
| David Lemus | M | 61 | 6 years | |
| Susan Lowther | F | 65 | 3 years | |
| Michael Bretherton | M | 68 | 4 years | |
| William Paris | M | 73 | 3 years | |
| Michael Davidson | M | 67 | 3 years | |
| Bryan Dulhunty | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 8 years |
| Simon Dew | M | - | 2 years | |
| J.P. Gabriel | M | - | 1 years | |
| Natalie Berner | F | 34 | 3 years | |
| Oliver Schon | M | - | 3 years | |
| Karen R. Krumeich | F | 70 | 2 years | |
| Suzanne Hancock | F | - | 7 years | |
| Eric Fink | M | - | 2 years | |
| James Ede-Golightly | M | 44 | 5 years | |
| Peter Roelvink | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 9 years |
| Peter J. Collum | M | - | 3 years | |
| Linnea Corwin Elrington | F | - | 7 years | |
| Simon Dixon | M | - |
Biomer Technology Ltd.
 Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Ian Harris | M | - |
Biomer Technology Ltd.
Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Duncan Fitzwilliams | M | - |
Biomer Technology Ltd.
Biomer Technology Ltd. Pharmaceuticals: MajorHealth Technology Biomer Technology Ltd. designs and develops biomaterial products for medical device industry. It develops medical device and therapeutic applications, and engineered polymers; designing and manufacturing industrial grade polymers, including high temperature polyurethanes HTTPU’s, for component and device manufacture. The company was founded in 2003 by Iain Gladstone Ross and is headquartered in Runcorn, the United Kingdom. | - |
| Anna Sandham | F | - | 1 years | |
| Eric Floyd | M | 62 | 5 years | |
| Matilda Bingham | M | - |
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The private company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | 9 years |
| Shaun Stapleton | M | - | 9 years | |
| Paul A. Sherman | M | - | 3 years | |
| Curtis Rambaran | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mel Bridges | M | 73 |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 11 years |
| Norman Molyneux | M | 68 | 7 years | |
| Diana Bartlett | F | 62 | 8 years | |
| Gregory West | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 7 years |
| David Venables | M | - |
Ark Therapeutics Group Plc
 Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 3 years |
| Martyn D. Williams | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 14 years |
| Mark Rothera | M | 62 | 2 years | |
| Seppo Ylä-Herttuala | M | - |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 16 years |
| Catherine Isted | F | - | 2 years | |
| David James Stuart Hetzel | M | - | 4 years | |
| Peter William French | M | - |
Benitec Biopharma Ltd.
Benitec Biopharma Ltd. BiotechnologyHealth Technology Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia. | 6 years |
| Steven Medlicott | M | 59 | 6 years | |
| Susan MacLeman | F | - | 4 years | |
| Timothy Corn | M | 73 | 10 years | |
| Cristyn Humphreys | F | - | - | |
| Neil David Murray | M | 60 | 7 years | |
| Tracie Elizabeth Ramsdale | M | 62 | 6 years | |
| Stephen Parker | M | 65 | 6 years | |
| Brendan Middleton | M | - | 4 years | |
| Steven John Mercer | M | - | 11 years | |
| Roger Brian Clarke | M | 76 | 12 years | |
| John Paul O'Connor | M | 75 | 5 years | |
| Gabrielle Heaton | F | - | 5 years | |
| Gordon Hirsch | M | - | 1 years | |
| Stephen Squire Foster | M | 72 | 2 years | |
| Ian M. Phillips | M | - | 2 years | |
| Peter Gunning | M | - | 2 years | |
| Barry French | M | - | - | |
| Juliet Thompson | F | 57 | 2 years | |
| Daniel Smith | M | - | 1 years | |
| Barbara A. Ruskin | M | - | - | |
| Will Evans | M | - | 2 years | |
| Joseph Rubinfeld | M | 91 | 2 years | |
| Olav Hellebø | M | 59 | 8 years | |
| Sean Torquil Nicolson | M | 58 | 10 years | |
| Raymond Barlow | M | 55 | 3 years | |
| David Solomon | M | 63 | 2 years | |
| Jeremy Curnock-Cook | M | 75 | - | |
| James Garner | M | - | 7 years | |
| Andrew Nicholas Branson | M | - | - | |
| Karl Hård | M | 62 | 1 years | |
| Philip Haworth | M | 68 | 1 years | |
| Stuart Black | M | 69 | 6 years | |
| Drummond McKenzie | M | - | - | |
| Christine Soden | F | 66 | 3 years | |
| Charles Spicer | M | 59 |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | 2 years |
| Jeremy Randall | M | 60 | 5 years | |
| John Melvyn Davies | M | 68 | 14 years | |
| Robert Quinn | M | 41 | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 71 | 71.00% |
| Australia | 28 | 28.00% |
| United States | 2 | 2.00% |
| Sweden | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Iain Ross
- Personal Network
